查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1794458

全球月經藥物市場

Menstrual Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 290 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球月經藥物市場規模將達 124 億美元

全球月經藥物市場規模預計在2024年達到84億美元，預計在2024-2030年的分析期內將以6.8%的複合年成長率成長，到2030年將達到124億美元。激素類藥物是本報告分析的細分市場之一，預計其複合年成長率將達到6.5%，到分析期結束時將達到48億美元。止痛藥細分市場在分析期間內的複合年成長率預計為7.8%。

美國市場規模估計為 23 億美元，中國市場預計複合年成長率為 10.6%

美國月經藥物市場規模預計2024年達到23億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到26億美元，在分析期間（2024-2030年）的複合年成長率為10.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為3.4%和6.6%。在歐洲，德國的複合年成長率預計為4.5%。

全球月經藥物市場－主要趨勢與促進因素摘要

為什麼月經藥物在女性保健領域受到如此廣泛的認可？

隨著全球對月經健康認知的提高以及圍繞月經的偏見逐漸消退，月經藥物越來越被認為是女性整合保健的重要組成部分。這些藥物旨在控制各種與月經有關的症狀，包括經痛、月經（大量出血）、月經症候群（PMS）和月經症候群（月經月經於荷爾蒙避孕藥或非處方止痛藥，但更有針對性的藥物的發展擴大了可用的治療範圍。非類固醇消炎劑（NSAID）、荷爾蒙療法、解痙藥和血清素再回收抑制劑常用的處方藥，可針對特定症狀提供各種解決方案。隨著女性在生殖健康管理方面更加積極主動，已開發國家和開發中國家對月經藥物的需求都在增加。教育宣傳活動、社群媒體宣傳以及醫療保健提供者的倡導，正在進一步打破圍繞月經的文化沉默。各國政府和非政府組織也擴大將月經管理納入其公共衛生工作，尤其是在學校健康計畫和以女性為中心的推廣活動中。這些共同的努力正在創造一種環境，使衛生藥物不再被視為可有可無的，而是被視為女性身心和社會福祉的核心。

藥物創新如何改變月經藥物的有效性和安全性？

醫藥領域的進步正在提升月經藥物的療效和安全性，在改善患者預後和增強患者對治療方案的信心方面發揮關鍵作用。其中最重要的進展之一是荷爾蒙治療方法的演變，如今荷爾蒙療法的劑量更低，給藥機制也更具針對性，從而在最大程度提高療效的同時最大限度地減少副作用。延長週期的口服避孕藥、釋放荷爾蒙的避孕器(IUD) 和經皮貼片為患有慢性月經失調的女性提供了長期解決方案。同時，新一代非類固醇消炎劑(NSAID) 的胃腸道耐受性得到改善，它們正在被引入，以更安全地緩解月經，尤其是長期使用。生物技術也促進了月經健康的創新，相關研究正在探索基因表現和荷爾蒙調節，以更好地理解和治療子宮內膜異位症和經前煩躁症 (PMDD) 等疾病。此外，數位療法和基於應用程式的平台開始與藥物解決方案相結合，幫助女性追蹤症狀並最佳化治療時機，從而獲得最大益處。藥物研發人員越來越注重個人化醫療方法，並意識到月經健康狀況受遺傳、生活方式和並存健康狀況的影響差異很大。此外，他們也正在努力開發非荷爾蒙療法，以應對無法或不願使用荷爾蒙的女性，進一步擴大治療的整體性。這些創新不僅提高了月經藥物的治療價值，也減少了先前與長期治療計畫相關的猶豫和恐懼，尤其是在青少年和首次使用者中。

文化規範和當地醫療保健如何影響月經藥物的採用？

文化信念、醫療基礎設施和當地認知程度顯著影響著世界各地對月經藥物的接受程度。在已開發國家，醫療保健服務相對普及，女性健康話題也更加普遍，常規婦科護理和藥物的廣泛供應為月經藥物的使用提供了支持。相較之下，在許多開發中地區和低收入地區，社會文化禁忌、宗教限制和錯誤訊息仍然阻礙女性就醫治療月經失調。因此，許多女性選擇家庭療法或默默忍受症狀，延誤了診斷和治療。然而，由於倡導團體、國際衛生組織以及旨在使月經世俗化和促進月經平等的教育宣傳活動的努力，這種趨勢正在逐漸改變。行動診所、學校健康計畫和遠端醫療平台正在改善農村和服務匱乏人群獲得月經藥物和資訊的管道。經濟因素也會影響女性接受長期治療的能力。一些國家的政府已開始對月經藥物提供補貼或將其納入基本藥物清單，鼓勵其更廣泛地使用並納入初級衛生保健服務。此外，將月經健康教育納入學校課程，也使年輕女性掌握了相關知識，並增強了她們的信心，從而能夠更早地尋求醫療協助。這些不斷變化的社會動態正在逐步重塑月經藥物市場，使其更具包容性，並更好地應對地區多樣性和醫療保健差異。

加速全球月經藥物市場成長的關鍵促進因素有哪些？

月經藥物市場的成長受到多種相互關聯的趨勢的推動，包括醫療政策、藥物創新、消費行為和社會變革。首先，多囊性卵巢症候群、子宮內膜異位症和嚴重月經等月經紊亂疾病的盛行率不斷上升，這推動了對有效藥物介入的臨床需求。其次，已開發市場和新興市場醫療保健管道的擴大和保險覆蓋範圍的擴大，使月經治療更加經濟實惠且更加普及。第三，隨著社會變得更加開放，月經恥辱感正在消除，越來越多的女性開始尋求醫療解決方案，而不是默默忍受痛苦。第四，包括非荷爾蒙藥物和植物來源藥物開發在內的多樣化治療方案正在吸引更多具有不同需求和偏好的使用者。第五，數位健康平台的擴展促進了遠距諮詢和個人化治療計劃的製定，使女性更容易開始和管理自己的治療。第六，由以女性為中心的品牌和健康組織主導的有針對性的行銷宣傳活動和宣傳活動正在教育消費者並提高產品知名度。第七，公營和私人公司對女性健康的投資不斷增加，加速了更安全、更有效的月經療法的研發。最後，將月經健康納入全球生殖健康和保健議程，鞏固了月經在長期醫療保健規劃中的重要性。這些驅動力共同造就了更成熟、更有韌性的月經藥物市場，支持全球採取積極主動、穩健的月經健康管理方法。

部分

藥物類型（荷爾蒙治療、緩解疼痛、PMS/PMDD 治療、月經調節、其他藥物類型）、給藥途徑（口服、注射給藥、局部給藥）

受訪公司範例

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare（Zydus）
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma（a Perrigo company）
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.（MSD）
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP37367

Global Menstrual Drugs Market to Reach US$12.4 Billion by 2030

The global market for Menstrual Drugs estimated at US$8.4 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Hormonal Treatment Drugs, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Pain Relief Drugs segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 10.6% CAGR

The Menstrual Drugs market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Menstrual Drugs Market - Key Trends & Drivers Summarized

Why Are Menstrual Drugs Gaining Broader Acceptance in Women’s Healthcare?

Menstrual drugs are increasingly being recognized as essential components of comprehensive women’s healthcare, as global awareness about menstrual health rises and stigmas surrounding menstruation continue to erode. These medications are designed to manage a wide array of menstrual-related conditions such as dysmenorrhea (painful periods), menorrhagia (heavy bleeding), premenstrual syndrome (PMS), and premenstrual dysphoric disorder (PMDD). For many women, these drugs significantly improve quality of life by reducing pain, regulating cycles, and stabilizing mood fluctuations. Traditionally, the treatment of menstrual issues was limited to hormonal contraceptives or over-the-counter pain relievers, but the development of more targeted pharmaceutical options has expanded the therapeutic landscape. Non-steroidal anti-inflammatory drugs (NSAIDs), hormonal therapies, antispasmodics, and serotonin reuptake inhibitors are now commonly prescribed, offering diverse solutions tailored to specific symptoms. As women become more proactive about managing their reproductive health, the demand for menstrual drugs is growing across both developed and developing regions. Educational campaigns, social media awareness, and healthcare provider advocacy have further reduced the cultural silence surrounding menstruation. Governments and NGOs are also increasingly including menstrual management as part of public health initiatives, especially in school health programs and women-focused outreach. These collective efforts are creating an environment where menstrual drugs are no longer viewed as optional but are instead recognized as central to women's physical, emotional, and social well-being.

How Are Pharmaceutical Innovations Transforming the Effectiveness and Safety of Menstrual Drugs?

Pharmaceutical advancements are playing a critical role in enhancing both the effectiveness and safety profile of menstrual drugs, leading to better patient outcomes and greater confidence in treatment options. One of the most significant developments is the evolution of hormone-based therapies, which are now being engineered with lower doses and more targeted delivery mechanisms to minimize side effects while maximizing efficacy. Extended-cycle oral contraceptives, hormone-releasing intrauterine devices (IUDs), and transdermal patches are offering long-term solutions for women with chronic menstrual disorders. In parallel, newer generations of NSAIDs with improved gastrointestinal tolerability are being introduced to manage menstrual pain more safely, especially for long-term use. Biotechnology is also contributing to innovation in menstrual health, with research exploring gene expression and hormonal modulation to better understand and treat conditions like endometriosis and PMDD. Additionally, digital therapeutics and app-based platforms are beginning to be paired with pharmacological solutions, helping women track symptoms and optimize treatment timing for maximum benefit. Drug developers are increasingly focusing on personalized medicine approaches, recognizing that menstrual health varies widely based on genetics, lifestyle, and co-existing health conditions. Efforts are also underway to develop non-hormonal therapies for women who are unable or unwilling to use hormonal drugs, further broadening treatment inclusivity. These innovations are not only improving the therapeutic value of menstrual drugs but also reducing the hesitation or fear previously associated with long-term treatment plans, especially among adolescents and first-time users.

How Do Cultural Norms and Regional Healthcare Access Influence the Adoption of Menstrual Drugs?

Cultural beliefs, healthcare infrastructure, and regional awareness levels greatly influence the adoption of menstrual drugs across different parts of the world. In developed countries, where healthcare access is relatively widespread and conversations around women’s health are more normalized, the usage of menstrual drugs is supported by routine gynecological care and broad pharmaceutical availability. In contrast, in many developing and low-income regions, socio-cultural taboos, religious restrictions, and misinformation still hinder women from seeking medical assistance for menstrual disorders. As a result, many women rely on home remedies or endure symptoms in silence, delaying diagnosis and treatment. However, this trend is gradually changing, thanks to the efforts of advocacy groups, international health organizations, and educational campaigns aimed at destigmatizing menstruation and promoting menstrual equity. Mobile clinics, school-based health programs, and telemedicine platforms are improving rural and underserved populations’ access to menstrual drugs and information. Economic factors also play a role, as the affordability of drugs influences whether women can commit to long-term treatment. Governments in some countries are beginning to subsidize or include menstrual drugs in essential medicine lists, which is encouraging broader use and integration into primary healthcare services. Furthermore, the inclusion of menstrual health education in school curricula is equipping young women with the knowledge and confidence to seek medical help early. These shifting social dynamics are steadily reshaping the menstrual drug market, making it more inclusive and responsive to regional diversity and healthcare disparities.

What Are the Main Drivers Accelerating the Growth of the Global Menstrual Drugs Market?

The growth in the menstrual drugs market is driven by several interrelated trends across healthcare policy, pharmaceutical innovation, consumer behavior, and societal change. First, the rising prevalence of menstrual disorders such as PCOS, endometriosis, and severe dysmenorrhea is fueling clinical demand for effective pharmaceutical interventions. Second, increasing healthcare access and insurance coverage in both developed and emerging markets are making menstrual treatments more affordable and widespread. Third, greater societal openness and the destigmatization of menstruation are encouraging more women to seek medical solutions rather than suffer in silence. Fourth, the diversification of treatment options, including the development of non-hormonal and plant-based drugs, is attracting a wider range of users with different needs and preferences. Fifth, the expansion of digital health platforms is facilitating remote consultations and personalized treatment plans, making it easier for women to initiate and manage their care. Sixth, targeted marketing campaigns and awareness initiatives led by women-centric brands and health organizations are educating consumers and improving product visibility. Seventh, increased investment in women’s health by both public agencies and private pharmaceutical companies is accelerating research and development of safer, more effective menstrual therapies. Lastly, the integration of menstrual health into global reproductive health and wellness agendas is cementing its importance in long-term healthcare planning. Collectively, these drivers are contributing to a more mature and resilient menstrual drug market, one that supports a proactive and empowered approach to managing menstrual health around the world.

SCOPE OF STUDY:

The report analyzes the Menstrual Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs, Other Drug Types); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare (Zydus)
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma (a Perrigo company)
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Menstrual Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Menstrual Health Throws the Spotlight on Therapeutic Solutions for Pain and Cycle Regulation
    • Increased Diagnosis of Conditions Like Endometriosis and PCOS Propels Growth in Hormonal and Anti-Inflammatory Drug Use
    • Growing Demand for Non-Opioid Pain Relief Expands the Addressable Market Opportunity for NSAIDs and Natural Alternatives
    • Shift Toward Over-the-Counter and Self-Care Solutions Strengthens the Business Case for Easily Accessible Menstrual Medications
    • Evolving Societal Attitudes Toward Menstrual Wellness Accelerate Demand for Targeted, Symptom-Specific Drugs
    • Product Innovation in Extended-Release and Combination Formulations Drives Adoption Among Younger Demographics
    • Rising Use of Oral Contraceptives for Menstrual Management Spurs Dual-Benefit Drug Utilization
    • Telehealth and DTC Women's Health Platforms Throw the Spotlight on Digital Access to Menstrual Prescriptions
    • Increased Focus on Quality of Life and Workplace Productivity Supports Greater Use of Period Pain Medications
    • Demand for Plant-Based and Hormone-Free Menstrual Relief Products Drives Growth in Complementary Therapies
    • Clinical Interest in Personalized Medicine and Hormone Profiling Expands Potential for Tailored Menstrual Drug Regimens
    • Menstrual Tracking Apps and Digital Health Tools Generate Insights That Spur Demand for Proactive Pharmaceutical Interventions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Menstrual Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hormonal Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Pain Relief Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for PMS & PMDD Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Menstrual Regulation Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • INDIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AFRICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030

IV. COMPETITION